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Abstract Chronic rhinosinusitis is a heterogeneous and multi-
factorial disease with unknown etiology. Aberrant responses to
microorganisms have been suggested to play a role in the
pathophysiology of the disease. Research has focused on the
presence, detection, response to, and eradication of these poten-
tial threats. Main topics seem to center on the contribution of
structural cells such as epithelium and fibroblasts, on the con-
sequences of activation of pattern-recognition receptors, and on
the role of antimicrobial agents. This research should be viewed
not only in the light of a comparison between healthy and
diseased individuals, but also in a comparison between patients
who do or do not respond to treatment. New players that could
play a role in the pathophysiology seem to surface at regular
intervals, adding to our understanding (and the complexity) of
the disease and opening new avenues that may help fight this
incapacitating disease.
Keywords Innateimmunity.Chronicrhinosinusitis.
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Introduction
Research into the workings of the innate immune system is
slowly developing from the dark horse it once was into a
frontrunner with the realization that the innate immune
system is an integral part of immunity. By definition, the
innate immune system is that part of the immune system that
does not depend on previous exposures for optimal function.
Its main functions are largely to act as a physical and
chemical barrier, to recruit immune competent cells to the
site of infection, to activate the adaptive immune system,
and to activate the complement system. In this light, the
innate immune system seems to buy time for the adap-
tive immune system to come to the rescue. However, it
can also act as a fully accomplished eradicating defense
system, avoiding the energy-consuming mobilization of
the adaptive immune system. Research on the innate
immune system over the years had focused on a number
of larger topics. The first topic was the diverse role of
(airway) epithelium in the innate defense. As the epi-
thelium forms the outer layer of an organism, it is well-
positioned to detect and respond to changes in the
environment [1]. The second topic was the activity of
different receptors by which cells can detect the outside
environment, and the third was the action of (secreted)
mediators that fight off potential threats. This review
builds on the 2009 paper on the role of innate immunity
in the pathogenesis of chronic rhinosinusitis (CRS) by
Andrew Lane in this same journal [2￿￿]. Starting from
this point, in the first part of this review, we update and
extend previous work, but in the second part, we focus
on two main trends that could shape research, not only
in the field of innate immunity, but also in the field of
CRS and nasal polyposis (NP) [3, 4￿, 5￿].
The relationship between innate immunity and CRS has
always been special. In cystic fibrosis, there is an absence of
mucociliary clearance and a high prevalence of CRS. The
presence of biofilms in CRS patients and the postulated
roles for Staphylococcus aureus, viruses, and fungi in the
pathogenesis of CRS over the years have all been based on a
disrupted ability to fight off these microorganisms. Given
that it is not clear to what extent the adaptive immune
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by superantigens, non–IgE-mediated antifungal response,
local production of IgE in the absence of systemic allergy)
in the complex inflammation of CRS [6, 7], it seems logical
thattheinnateimmunereactionsaresocarefullyconsideredin
the pathogenesis of CRS. We should, however, also not
forget that CRS is not a single disease. Not only do some
patients with CRS suffer from NP (while others do not),
the differences in cellular composition between “Asian”
(neutrophilic) and “Caucasian” (eosinophilic) polyps [8, 9]
could even suggest that the strong focus we have placed on
particular inflammatory cells in the pathogenesis of CRS has
no merit. Moreover, CRS without NP may have different
etiologies in different patients, which would make it difficult
to find a common adaptive or innate immune response
deficiency as the root course of the disease.
Chronic Rhinosinusitis and the Outside Microbial World
Although CRS with NP inflammation is clearly associated
withexaggeratedproductionof T-helpertype 2(Th2)cytokines
and pro-eosinophilic mediators [6, 7], the underlying
cause remains unknown. Multiple groups have proposed
that abnormal immune responses may accompany exposure
to microorganisms and/or their products, including fungi,
S. aureus, or bacterial biofilms [10–12]. This line of
thought remained a main topic of research.
Given the postulated role of microorganisms in the
pathogenesis of CRS or nasal polyposis, it seems reasonable
to assume that trying to fight (specific) pathogens through
medication would prove advantageous. However, unfortu-
nately, there is at best modest success with this approach.
Multiple placebo and controlled studies with antifungals
showed no beneficial effect [13–15]. Despite the initial
success [16], a recently published meta-analysis also
showed that even placebo did better than the active arm
[17]. The use of antibiotics or macrolides yields varying
results with modest effect for roxithromycin [18]a n df o r
doxycycline [19], whereas an international study with
low-dose azithromycin yielded no effect on multiple clinical
parameters [20].
It is important to stress that the modest effect of
antimicrobial treatment does not imply that innate immunity
is not relevant for CRS or NP, as treating single classes of
pathogens would still leave others (fungi vs bacteria vs virus);
with microorganisms all around us, recolonization could be
very rapid; and preventing growth of microorganisms or
induction of their killing should still lead to the release of
pathogen-associated ligands that could trigger the innate
response. Interesting, although not related to the fight
against pathogens but rather related to the Th2-like inflamma-
tion seen in CRS/NP, is the experimental use of an antibody
directed against interleukin (IL)-5 [21, 22]. An international
consortium is currently evaluating these promising initial
clinical results further in a larger study.
Chronic Rhinosinusitis and the Detection
of Microorganisms
Toll-like receptors (TLRs) have been at the forefront of
research into innate immunity. As such, they are the best
described family of receptors by which cells can detect
microorganisms in their environment [1]. Also in CRS-
related research, there has been great interest in these
receptors as triggers of innate immune reactions. However,
recent findings show that we probably need to broaden our
view. One of the first negative results comes from the field of
TLR2, in which despite previous observations of a link
between lower expression of TLR2 and difficult-to-treat
CRS [23], none of the investigated polymorphisms in the
TLR2 gene could be linked to the disease [24]. Interestingly,
one possible explanation is that we should not consider one
receptor or one trigger in isolation. Although the design of the
study would have been better with the inclusion of more than
one concentration of stimuli, Nonaka and coworkers [25]
showed that in fibroblasts isolated from allergic NP patients,
the sole addition of TLR2 to TLR5 agonists or IL-4 did
not reveal any induction of the T-lymphocyte–associated
mediatorTARC(thymusandactivation-regulatedchemokine).
However, when the TLR agonists were combined with IL-4,
a strong induction was seen [25]. Although this observation
could be related to the allergic phenotype and not to the CRS
background of the patients in this study, this outcome does
show that we should more carefully consider interaction
between triggers, especially because in everyday life, we
seldom encounter single triggers. The same group,
however, also showed that nasal polyp fibroblasts are
able to respond to the sole addition of TLR2 to TLR5
agonists via the production of macrophage inflammatory
protein-3α [26].
The horizon is also broadened by the observation that an
additional family of innate immunity receptors is also
affected in CRS and NP. These NLR receptors (NOD-
like receptors) are found within the cytoplasm of cells
and can also be triggered by microbial-derived factors
[1]. Three of these receptors (NOD-1, NOD-2, and
NALP-3) were investigated in NP and were shown to
be highly enriched in the epithelia of patients relative to
healthy controls and shown to be downregulated by
steroid treatment [27]. In addition to the NLR class of
receptors, an as-yet-unknown receptor is held responsible
for the detection and responsiveness of airway epithelia
to chitin [28]. Chitin, a cell wall component not found in
humans, is able to induce expression in air-interface–grown
epithelial cells of an enzyme that is able to break down
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eotaxin-3, a mediator important in the functionality of
eosinophils. Increased expression of AMCase and eotaxin-3
is also connected to treatment efficacy, in which polyps that
respond well have higher levels of AMCase and eotaxin-3
than those that respond more poorly.
Chronic Rhinosinusitis and the Battle
Against Microorganisms
Lysozyme is a major component of nasal secretions and was
always seen as an important antibacterial defense protein
given its ability to break down bacterial cell wall. Woods
and coworkers [29] now have shown that lysozyme can also
play a role in the fight against fungi, as growth in cultures
from multiple species, including Aspergillus, Penicillium,
and Candida, is susceptible to lysozyme. This was also true
for clinical isolates from CRS patients, showing that
selection of fungi not responsive to lysozyme is not part
of the pathological mechanism in CRS. Whether or not
changes in lysozyme activity or expression could be
involved in CRS remains to be explored. That changes
in activity of antimicrobial agents could play a role is
seen for lactoferrin. At both the gene expression level
and the protein level, it was shown that lactoferrin was
reduced in CRS patients compared with controls [30].
Small cationic peptide–like defensins and cathelicidins
(LL37) make up the third important class of antimicrobial
agents and have been described previously [2￿￿], but a recent
development was the realization that small lipids (cholesteryl
esters) [31] that can be found in breast milk also can be found
atincreasedlevelsinnasalsecretionsfromCRSpatients[32￿].
Interestingly, expression of antimicrobial agents is highly
variable among individuals suffering from disease [33]a n d
may also depend on the colonization status of S. aureus in NP
patients [34].
A Global View on Innate Immunity and Chronic
Rhinosinusitis
New lines of research seem to abandon the thought that a
unique molecule, cell, or pathogen could be the single
source of CRS in all patients. With the technical develop-
ments in genetics, transcriptomics, and proteomics, a more
generalized approach is chosen. Although these approaches
may suffer from their own restrictions [35], they can provide
a broader picture. Perhaps even more importantly, as these
methods collect a wide range of (molecular) data on single
individuals, they may aid in defining molecular patterns that
could point to subtypes of CRS and/or help explain the
widely varying success rates of treatment among individuals
suffering from CRS.
Polymorphisms and Chronic Rhinosinusitis
Genome-wide association studies focus on differences at the
genomic level between cases and controls. These differences
are at the DNA sequence level, of which single nucleotide
polymorphisms (SNPs) are the most commonly investigated
a n di nw h i c hc a s e sc o u l dr e p r e s ent individuals suffering
from CRS or individuals with CRS who respond poorly to
treatment. The rational is that SNPs could have consequences
for the expression level of a given gene when the mutations
are located in promoter or enhancer elements, or that these
mutations could have consequences for the activity of the
proteins encoded by the gene in question when the mutation
is in the coding sequences. The elegant design used by the
groupofDesrosiersetal. hasidentifieda growinglistofSNPs
in a growing list of genes that were shown to be different
between a group of more than 200 CRS patients and close to
190 postcode-matched controls in Canada [24, 36–41]. The
roles of the genes involved vary but seemed to center on
the detection of potential pathogens [24], the detection of
mediators [36, 37], and downstream signaling events
[38–41]. Given the uniqueness of this group of cases
and controls, it would be interesting and important to
study the functional consequences of the discovered
SNPs. Moreover, given that the genes belong to the
larger group of signaling-related genes, it would be relevant
to determine whether or not a correlation exists between the
polymorphisms in the different genes. That the SNPs are all
discovered in the same group of individuals does not
necessarily imply that the polymorphisms in different
genes coexist in the same individual. The potential relation-
ship between these genes (and their SNPs) would provide a
deeper understanding of the potential processes involved in
the pathogenesis of CRS.
Some of the mutation studies focus on SNPs in genes that
are directly linked to previous parts of this review, reflecting
the absence of specific SNPs in TLR2 linked to CRS [24]o r
the presence of mutations linked to the functionality of the
newly discovered innate lymphoid cell (ILC)2 (described in
further detail subsequently) [36, 37]. One study focuses on
SNPs within a member of the SERPIN family [41]. This
family of proteins is named after the proteins’ ability to
inhibit the protease activity of serine proteases. One of the
important target molecules of SERPIN-A1 is the elastase
produced by neutrophils. This protease can be released from
neutrophils after exposure to bacterial superantigens or
allergens and could therefore contribute to the ongoing
inflammation in CRS. Indeed, one of the SNPs investigated
was linked to a nearly sixfold increase in the risk of
developing CRS. Whether this mutation had consequence
for the activity or SERPIN-A1 or its secretion was not
investigated.Incontrast,noSNPsinglutathioneS-transferase,
a gene linked to redox state, could be linked to CRS [42].
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The analysis of the transcriptome (the collection of mRNAs
that are expressed) has also found its way in the study of the
involvement of innate immunity in CRS. Several studies
have specifically focused on innate immunity through the
use of dedicated arrays (or polymerase chain reaction–based
technologies) [43, 44], while others have investigated the
complete transcriptome through microarray technologies
[45–48]. The later studies can be seen to describe the
potential consequences of the involvement of the innate
immune system and other aspects of the disease that are
not necessarily linked to innate immunity.
In a screen, among the expression of 125 TLR-related
genes in nonatopic CRS patients and controls, 23 genes
were shown to be differentially regulated [43]. Four genes
were upregulated and 19 genes downregulated. Among the
genes that were upregulated in disease were TLR9 and
TLR10, while among the genes that were downregulated, a
substantial number belong to the JNK/p38 pathway. It is
interesting to see that of the three main pathways [1] that are
downstream of the TLRs (the nuclear factor-κB [NF-κB]
pathway leading to activation of the NF-κB-family of
transcription factors, the JNK/p38 pathway leading to
the activation of the AP1 family of transcription factors,
and the IRF pathway leading to the activation of type 1
interferons), one pathway is so strongly affected. The
increased expression of TLR9 contrasts previous findings
[23] that showed a reduced expression of TLR9. The
reason for this difference is not clear, but it could be
related to differences in the allergic status among the
participants in these two studies—nonatopic in the study
of Zhao and coworkers [43], (partly) atopic in the study
of Lane and colleagues [23]. The question remains as to
what are the functional consequences of the observed
deregulation of genes, with on one hand the upregulation
of the TLR receptor, and on the other hand a downregulation
ofpartofthe downstreamsignaling cascade.Thecomplement
system is the focus of the study by Schlosser et al. [44]. The
complement system is important in the direct battle against
pathogens that have penetrated the peripheral barriers.
Overactivation of this system may result in uncontrolled
inflammation, whereas inactivity may fail to eradicate
potential threats. This is the first study to address the
complement system in detail, although expression of a com-
plement factor (C3) in CRS has been described previously
[49].A stronglyincreased expressionoffactorB(sixfold) and
C3 (fourfold) was detected relative to controls in combination
with a small increase in the terminal protein C5 (twofold) and
no change in C7. Although most of the complement factors
are produced in the liver, the increased expression of
factor B and C3 not only suggests the involvement of
the alternative pathway of activation, but also that these
factors (in the absence of increased expression of the
terminal proteins) could be locally produced by the airway
epithelial cells [50]. The other microarray [45–48]a n d
proteomic [51–55] studies, by their nature, have not
investigated the involvement of the innate immunity directly
but show (in addition to innate immunity–related genes and
proteins) the global effects of the ongoing inflammation
and its potential use as a predictor of treatment outcome
or clinical classification.
A New View on Innate Immunity and Chronic
Rhinosinusitis
The immunology field recently witnessed an interesting
development in the discovery of an extended family of ILCs
that seem to play an important role in tissue remodeling and
in the defense against microorganisms and helminthic
parasites [56]. ILCs have been described previously, with
natural killer (NK) cells and lymphoid tissue inducer
(LTi) cells as the best known protagonists [57, 58].
New members of the ILC family share characteristics of
NK cells and LTi cells in that they not only express NK
markers such as NKp44 and NKp46, but also LTi
markers such as CD127 (IL-7 receptor chain α)a n dt h e
transcription factor RORγt[ 56]. Moreover, these cells
are able to produce IL-17 or IL-22 and in this respect
resemble some of the different subtypes of Th cells that
play such an important role in the different branches of
the adaptive immune system. The parallel with the adaptive
immune system was further strengthened by the descrip-
tion of an ILC type that is able to produce the archetypal
Th2 cytokines IL-5 and IL-13. Given their ability to
produce IL-13, these cells have been named nuocytes
(after the 13th letter of the Greek alphabet) or ILC2s
(after their resemblance to Th2 cells) [59, 60]. They were
originally described only in mice gut, but we have recently
discoveredthatthiscelltypeishighlyenrichedinnasalpolyps
of CRS patients [61￿￿]. These cells produce IL-5 and IL-13
and respond to exposure to IL-25 and IL-33 produced by
several cell types in nasal polyps, including macrophages,
mast cells, and epithelial cells. This would tie in with the
observation that epithelial cells isolated from nonresponsive
polyps (return of visible polyps within 6 months after surgery
despite postoperative use of local and oral steroids) showed
higher basal mRNA levels of IL-33 than epithelial cells
isolated from responsive polyps [25, 62]. Moreover,
reports show that downstream of ILC2s, CRS with NP
is associated with lower levels of expression of the
epithelial IL-22 receptor compared with healthy individuals
or CRS patients without NP [63], and that polymorphisms in
the gene are correlated with disease severity [27]. Given the
ability of nasal epithelial cells to respond to IL-13 and IL-22,
Curr Allergy Asthma Rep (2012) 12:120–126 123such a potential should consider that IL-33 can also be
produced by fibroblasts and that IL-33 receptors can also
be found on mast cells, eosinophils, and Th2 lymphocytes
[12]. Despite these obvious restrictions, the negative or
positive feedback loop may contribute to the severity of
the disease or its treatment. However, it is noteworthy
that IL-33 mRNA levels are somewhat enhanced by the
TLR agonist CpG in epithelial cells from treatment-
resistant CRS, but not in epithelial cells from treatment-
responsive CRS [64] ,w h i c hw o u l da g a i nl i n kC R St o
aberrant antimicrobial immunity. Although the precise
role of ILCs in general and ILC2s in particular in immune
responses or the pathogenesis of CRS is still unknown, they
could offer some explanation for the Th2/eosinophilic-like
phenotype of NP without a prerequisite concomitant allergic
response. Given the absence of RAG recombinase-dependent
rearranged antigen receptors on ILCs, the immune responses
mediated by these cells are most likely polyclonal in nature.
However, exactly if and how ILC2s influence the evident
aberrant adaptive immune responses seen in CRS inflamma-
tion remains unclear. Whether the discovery of ILCs heralds
the end to the darkness that surrounds the pathogenesis of
CRSorjustaddsanotherlevelofcomplexitysurelywillbethe
topic of interesting new lines of research.
Conclusions
The marriage between CRS and/or NP remains strong, and
there are no signs that the link will get weaker. There does
seem to be a trend toward broader approaches that better
consider that CRS is not a single disease and that no single
pathogen, molecule, or cell is the cause of the disease.
Although there will always be a need for dedicated research
that would analyze the contribution of single pathogens,
molecules, or cells to the pathogenesis of the disease or to
its treatment success, techniques seem to have developed
sufficiently to try to take an even broader view. Collecting
data on the transcriptome, proteome, or metabolome (the
collection of mRNA, proteins, or metabolic products)
could assist in defining the disease in single individuals.
Even when a single process would be the sole cause of
CRS, the reason why this process is affected could be
different in every patient. With CRS being a collection of
different diseases in different patients, the need for a
holistic view seems even more important. It might well
be that our clinical options to categorize CRS are too
limited by the sheer limitation of the number of clinical
parameters we can use to describe the disease. In this
respect, the discovery and description of molecular patterns
may aid us in refining the clinical characterization of the
disease and provide a better understanding as to why some
treatments fail in certain individuals. CRS probably will
always keep surprising and fascinating us. The discovery of
a whole new class of innatelymphocytes that issoenriched in
NP probably will not be the last of these surprises.
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